Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Evaluate progression free survival between Pemetrexed 500 mg/m² every 3 weeks + Erlotinib 150 mg daily and Pemetrexed 500 mg/m² every 3 weeks when given as second line therapy for the treatment of locally advanced or metastatic nonsquamous Non Small Cell Lung Cancer
Inclusion criteria
- Patients who have histologically or cytologically documented diagnosis of nonsquamous NSCLC (Stage IIIA, IIIB or IV at entry), with progressive disease after treatment with 1 prior chemotherapy regimen for locally advanced or metastatic disease, who are considered for second line therapy and who meet the other disease criteria